CAS Number22204-53-1
SynonymsEquiproxen; piproxen; (+)-(S)-Naproxen; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; (2S)-2-(6-Methoxy-2-naphthyl)propanoic acid; Naproxen; Apronax; Naprosyne; Naproxene; (+)-NAPROXEN; (S)-(+)-6-methoxy-α-methyl-2-naphthaleneacetic acid; ALEVE; (S)-naproxen; Anaprox; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic Acid; Naproxeno; NAPRELAN; Naproxenum; MFCD00010500; (2S)-2-(6-Methoxynaphth-2-yl)propanoic acid; EINECS 244-838-7; (S)-(+)-Naproxen; Naprosyn
Molecular FormulaCH3OC10H6CH(CH3)CO2H
Molecular Weight230.26
Purity98, EP or BP Grade%
Density1.2±0.1 g/cm3
Boiling Point403.9±20.0 °C at 760 mmHg
Melting Point152-154 °C (lit.)
Appearancewhite powder
EINECS244-838-7
Symbol
Signal WordWarning
Please Login or Create an Account to: See VlP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 22204-53-1 |
| Catalog No. | 2A-9010213 |
| Chinese Name | 萘普生 |
| Synonyms | Equiproxen; piproxen; (+)-(S)-Naproxen; (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; (2S)-2-(6-Methoxy-2-naphthyl)propanoic acid; Naproxen; Apronax; Naprosyne; Naproxene; (+)-NAPROXEN; (S)-(+)-6-methoxy-α-methyl-2-naphthaleneacetic acid; ALEVE; (S)-naproxen; Anaprox; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic Acid; Naproxeno; NAPRELAN; Naproxenum; MFCD00010500; (2S)-2-(6-Methoxynaphth-2-yl)propanoic acid; EINECS 244-838-7; (S)-(+)-Naproxen; Naprosyn |
| Molecular Formula | CH3OC10H6CH(CH3)CO2H |
| Molecular Weight | 230.26 |
| Purity | 98, EP or BP Grade |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 403.9±20.0 °C at 760 mmHg |
| Melting Point | 152-154 °C (lit.) |
| Appearance | white powder |
| Water Solubility | Water solubility: insoluble; easily soluble in: al |
| Storage Condition | Keep receptacle sealed Store in a compact containe |
| Packaging | III |
| Application | Naproxen is an inhibitor of COX-1 and COX-2, with IC50 values of 8.72 and 5.15 μM respectively in cell assays. |
| EINECS | 244-838-7 |
| HTC | 2916399090 |
| PubChem ID | 329823070 |
| MDL Number | MFCD00010500 |
| SMILES | COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O |
| InChI | 1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1 |
| InChI Key | CMWTZPSULFXXJA-VIFPVBQESA-N |
| Beilstein/REAXYS | 3591068 |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | 6.1(b) |
| MSDS | msds/10213_1_22204_53_1.pdf |
| Bioactivity | Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Inflammation/Immunology Target COX-2:5.65 μM (IC50) COX-1:9.55 μM (IC50) In Vitro Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a well known nonsteroidal anti-inflammatory drug. Naproxen is approximately equipotent inhibitor of COX-1 and COX-2 in intact cells with IC50s of 2.2 μg/mL and 1.3 μg/mL, respectively[1]. In Vivo Naproxen exerts an anti-inflammatory and antifibrotic effect in mouse model of bleomycin-induced lung fibrosis. Naproxen also downregulates TGF-β levels and Smad3/4 complex formation[2]. Naproxen is shown to inhibit the time-courses of pain, fever and PGE2 with similar potencies (IC50=27, 40, 13 μM)[3]. Cell Assay BAEC are incubated for 30 min with Naproxen (0.1 ng/mL to 1 mg/mL). Arachidonic acid (30 μM) is then added, and the cells are incubated for a further 15 min at 37°C. The medium is then removed, and radioimmunoassay is used to measure the formation of 6-keto-PGF,a, PGE2, thromboxane B2, or PGF2a[1]. Animal Admin Rats[3] To measure the analgesic effects of naproxen in a carrageenaninduced model of monoarthritis, Male Sprague-Dawley rats (n=48, 217±28 g) are randomly divided into four groups of 12 by an internally developed computer program, allowing the blind performance of the behavioral experiment. To induce hyperalgesia by inflammation, animals in groups 1B, 1C, and 1D receive a 40-μL intra-articular injection of a saline solution containing 7.5 mg/mL carrageenan in the left hind limb under isoflurane anesthesia (time=−1 h). Animals in group 1A receive no injection. After 1 h (time=0) the animals in groups 1A, 1B, 1C, and 1D receive oral doses of naproxen in saline of 0, 0, 7.5 and 30 μmol/kg, respectively. The doses and time points of measurements are selected on the basis of simulations predicting measuring a full concentration-effect relationship within the time-span of the experiment[3]. Mice[2] Bleomycin (0.05 IU) is instilled intratracheally to C57BL/6 mice, which are then treated by micro-osmotic pump with vehicle, JNJ7777120 (40 mg/kg b.wt.), naproxen (21 mg/kg b.wt.), or a combination of both. Airway resistance to inflation, an index of lung stiffness, is assessed, and lung specimens are processed for inflammation, oxidative stress, and fibrosis markers[2]. References [1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [2]. Rosa AC, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther. 2014 Nov;351(2):308-16. [3]. Krekels EH, et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. Chemical & Physical Properties Density 1.2±0.1 g/cm3 Boiling Point 403.9±20.0 °C at 760 mmHg Melting Point 152-154 °C(lit.) Molecular Formula C14H14O3 Molecular Weight 230.259 Flash Point 154.5±15.3 °C Exact Mass 230.094299 PSA 46.53000 LogP 3.00 Vapour Pressure 0.0±1.0 mmHg at 25°C Index of Refraction 1.609 InChIKey CMWTZPSULFXXJA-VIFPVBQESA-N SMILES COc1ccc2cc(C(C)C(=O)O)ccc2c1 |
| Use of | Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. Properties Articles223 Name naproxen Synonym More Synonyms Naproxen Biological Activity Description Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Inflammation/Immunology COX-2:5.65 μM (IC50) COX-1:9.55 μM (IC50) In Vitro Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a well known nonsteroidal anti-inflammatory drug. Naproxen is approximately equipotent inhibitor of COX-1 and COX-2 in intact cells with IC50s of 2.2 μg/mL and 1.3 μg/mL, respectively[1]. References [1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [2]. Rosa AC, et al. Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment. J Pharmacol Exp Ther. 2014 Nov;351(2):308-16. [3]. Krekels EH, et al. Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats. Chemical & Physical Properties Molecular Formula C14H14O3 Exact Mass 230.094299 PSA 46.53000 Index of Refraction 1.609 InChIKey CMWTZPSULFXXJA-VIFPVBQESA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 30.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 United Nations shipping name European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (Naproxen) IMDG: TOXIC SOLID, ORGANIC, N.O.S. (Naproxen) International air transport hazard regulations: Toxic solid, organic, n.o.s. (Naproxen) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Digoxin | 20830-75-5 | 2A-9010147 |
| Dihydroartemisinin | 81496-81-3 | 2A-9010150 |
| Dihydroartemisinin | 71939-50-9 | 2A-9010151 |
| Dihydromorphine | 509-60-4 | 2A-9010158 |
| Diltiazem hydrochloride | 33286-22-5 | 2A-9010165 |
| Docetaxel | 114977-28-5 | 2A-9010215 |
| Donepezil hydrochloride | 120014-06-4 | 2A-9010227 |
| Donepezil Hydrochloride | 120011-70-3 | 2A-9010228 |
| Doripenem | 148016-81-3 | 2A-9010234 |
| Doxycycline hyclate | 24390-14-5 | 2A-9010246 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS